Crossmark Global Holdings Inc. Has $932,000 Holdings in Genmab A/S (NASDAQ:GMAB)

Crossmark Global Holdings Inc. lowered its position in Genmab A/S (NASDAQ:GMAB) by 45.9% during the third quarter, according to its most recent filing with the SEC. The firm owned 38,245 shares of the company’s stock after selling 32,387 shares during the period. Crossmark Global Holdings Inc.’s holdings in Genmab A/S were worth $932,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Russell Investments Group Ltd. boosted its position in Genmab A/S by 137.7% during the first quarter. Russell Investments Group Ltd. now owns 939 shares of the company’s stock valued at $28,000 after acquiring an additional 544 shares during the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Genmab A/S in the 1st quarter valued at about $43,000. Blue Trust Inc. boosted its position in shares of Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock valued at $108,000 after purchasing an additional 3,880 shares in the last quarter. Headlands Technologies LLC increased its holdings in Genmab A/S by 1,702.8% in the second quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after purchasing an additional 4,853 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. lifted its stake in Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares during the period. 7.07% of the stock is owned by institutional investors.

Genmab A/S Stock Performance

GMAB stock opened at $21.18 on Friday. The business has a 50-day simple moving average of $24.08 and a two-hundred day simple moving average of $26.28. The company has a market capitalization of $14.02 billion, a P/E ratio of 21.03, a price-to-earnings-growth ratio of 0.70 and a beta of 0.99. Genmab A/S has a 52-week low of $21.17 and a 52-week high of $32.89.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a return on equity of 14.64% and a net margin of 23.49%. The company had revenue of $816.10 million for the quarter, compared to the consensus estimate of $838.20 million. During the same quarter last year, the company posted $0.47 EPS. As a group, sell-side analysts forecast that Genmab A/S will post 1.28 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on GMAB shares. Truist Financial reduced their price objective on shares of Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Redburn Atlantic initiated coverage on shares of Genmab A/S in a research report on Tuesday, October 8th. They set a “buy” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a research report on Wednesday, October 16th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $45.20.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.